PDF(Pubmed)
Abstract：
Candida auris is a World Health Organization critical priority fungal pathogen. We conducted a systematic review to describe its epidemiology in Africa. PubMed and Google scholar databases were searched between January 2009 and September 2023 for clinical studies on C. auris cases and/or isolates from Africa. Reviews were excluded. We included 19 studies, involving at least 2529 cases from 6 African countries with the most, 2372 (93.8%), reported from South Africa. Whole-genome sequencing of 127 isolates identified 100 (78.7%) as clade III. Among 527 isolates, 481 (91.3%) were resistant to fluconazole, 108 (20.5%) to amphotericin B, and 9 (1.7%) to micafungin. Ninety of 211 (42.7%) patients with clinical outcomes died. C. auris is associated with high mortality and antifungal resistance, yet this critical pathogen remains underreported in Africa. Collaborative surveillance, fungal diagnostics, antifungals, and sustainable infection control practices are urgently needed for containment.
摘要：
耳念珠菌是世界卫生组织重要的重点真菌病原体。我们进行了系统评价，以描述其在非洲的流行病学。在2009年1月至2023年9月之间搜索了PubMed和Google学者数据库，以进行有关非洲C.auris病例和/或分离株的临床研究。评论被排除在外。我们纳入了19项研究，涉及来自6个非洲国家的至少2529例，2372（93.8%），来自南非的报道。127个分离株的全基因组测序鉴定出100个(78.7%)为进化枝III。在527个分离株中，481例(91.3%)对氟康唑耐药,108（20.5%）对两性霉素B，米卡芬净和9（1.7％）。211例临床结局患者中有90例（42.7％）死亡。弧菌与高死亡率和抗真菌药物耐药性有关，然而，这种重要的病原体在非洲仍未得到充分报道。协作监视,真菌诊断，抗真菌药,和可持续的感染控制措施是迫切需要遏制。
